BC Extra | Apr 10, 2019
Company News

Gilead cuts cardiopulmonary sales reps

Gilead said it will lay off about 150 cardiopulmonary sales representatives due to the anticipated market entry of generic versions of Letairis ambrisentan and Ranexa ranolazine. The decision was put into motion almost two years...
BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
BC Week In Review | Jul 27, 2018
Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO...
BC Extra | Jul 26, 2018
Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO...
BioCentury | Sep 9, 2017
Strategy

Some of the parts

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. could put the industry-leading CAR T pipeline in the hands of the company best-suited to expand the cell therapies into the as-yet-elusive solid tumor space....
BC Week In Review | Jul 14, 2014
Clinical News

Ranolazine: Phase II data

The double-blind, international Phase II HARMONY trial in 134 patients with paroxysmal AF showed that twice-daily 750 mg oral ranolazine plus 150 and 225 mg dronedarone each led to greater reductions in AF burden from...
BC Week In Review | Aug 19, 2013
Company News

Gilead, Lupin cardiovascular news

Gilead granted Lupin rights to launch a generic version of Gilead's angina drug Ranexa ranolazine on Feb. 27, 2019. The deal is part of a settlement of a 2010 suit Gilead filed in the U.S....
BioCentury | Aug 5, 2013
Regulation

Rushing to abandon tQT

FDA 's Norman Stockbridge wants to abandon thorough QT studies by 2015, replacing them with a preclinical assay suite better able to detect proarrhythmia side effects than existing assays. However, it remains unclear whether two...
BC Week In Review | Mar 18, 2013
Clinical News

Ranexa ranolazine: Phase IV data

The double-blind, international Phase IV TERISA trial in 927 evaluable chronic stable angina patients with concurrent Type II diabetes showed that Ranexa as an add-on to background antianginal therapy for 8 weeks met the primary...
BC Week In Review | Aug 20, 2012
Clinical News

CPAPP-A* test: Pivotal trial data

Beckman Coulter Inc. reported data from an analysis of 3,782 patients with non-ST-segment-elevation myocardial infarction (NSTEMI) ACS in the double-blind, placebo-controlled, international Phase III MERLIN-TIMI 36 trial of Ranexa ranolazine to treat ACS showing that...
Items per page:
1 - 10 of 277